Emerging β-lactam and β-lactamase inhibitor strategies for complicated urinary tract infections

Key Points

• The aim is to evaluate new β-lactam and β-lactamase inhibitor combinations for treating complicated urinary tract infections.
• Randomized trial with participants diagnosed with complicated urinary tract infections.
• Comparison of different β-lactam and β-lactamase inhibitor combinations for effectiveness and safety.
• Assessment of antibiotic resistance profiles before and after treatment.
• Significant improvement observed with the new β-lactam combinations versus standard treatments (HR 0.75, 95% CI 0.60-0.95, P=0.02).
• Reduction in recurrent infections by 30% with β-lactamase inhibitors compared to controls (RR 0.7, 95% CI 0.5-0.9, P=0.03).
• Enhanced susceptibility profiles for pathogens post-treatment, indicating effective management of antibiotic resistance.